Furthermore, Bortezomib enhanced the capacity of infused NK cells to clear a NKG2DL+ tumor in mice [89]; therefore, the possibility that proteasome inhibitors can stimulate in vivo NKG2D-mediated NK cell responses should be considered. This evidence concerns the gene KLRK1 and neoplasm.